Section Arrow
Quote
MNPR.NASDAQ
- Monopar Therapeutics Inc
Quotes are at least 15-min delayed:2026/02/20 06:28 EST
Pre Market
Last
 --
-- (--)
Bid
21.88
Ask
86.97
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 54.7
-0.78 (-1.41%)
Day High 
55.76 
Prev. Close
55.48 
1-M High
76.13 
Volume 
197.07K 
Bid
21.88
Ask
86.97
Day Low
52.845 
Open
55.21 
1-M Low
51.11 
Market Cap 
370.75M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 57.32 
20-SMA 62.99 
50-SMA 66.78 
52-W High 105 
52-W Low 26.055 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.96/-3.71
Enterprise Value
370.75M
Balance Sheet
Book Value Per Share
21.18
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.1967+0.0047+2.45%0.09PE
Pre Market 0.1931 -0.0036 -1.83%
IBRXImmunityBio8.61+0.07+0.82%-- 
Pre Market 8.5 -0.11 -1.28%
DRMADermata Therapeutics Inc1.93+0.65+50.78%0.08PE
Pre Market 1.57 -0.36 -18.65%
QNCXQuince Therapeutics0.1622-0.0158-8.88%-- 
Pre Market 0.162 -0.0002 -0.12%
LIMNLiminatus Pharma Inc0.2383-0.0066-2.69%-- 
Pre Market 0.232 -0.0063 -2.64%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.